Notice of results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.

Enquiries:

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	www.ekfdiagnostics.com Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker) Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	Tel: 020 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF's DiaSpect Tm hemoglobin analyzer supports anemia study in resource limited West Africa

Battery powered point-of-care analyzer demonstrated as ideal for operation in extreme temperatures and remote areas.

EKF at MEDLAB - Singapore 2019

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most established healthcare distributor

4th Annual AIDF Africa Summit

Meet EKF Diagnostics at AIDF 2019 in Nairobi, Kenya this February.

MEDLAB Middle East - Feb 2019

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.